Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 14, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute

BUFFALO, NY--(Marketwired - Dec 14, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI), Emory University and Roswell Park Cancer Institute (RPCI) today announced the publication of a study in...
November 30, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod

BUFFALO, NY--(Marketwired - Nov 30, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of two new patent applications by the U.S. Patent Office with claims that provide...
November 05, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress

BUFFALO, NY--(Marketwired - Nov 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter and nine-month period ended...
October 27, 2015 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5

BUFFALO, NY--(Marketwired - Oct 27, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2015, it will report its financial results for the third quarter and...
September 21, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Department of Defense Grants Cleveland BioLabs Second Award for Advanced Development of Entolimod as a Medical Radiation Countermeasure

BUFFALO, NY--(Marketwired - Sep 21, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP)...
September 16, 2015 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Publication of Studies Demonstrating Efficacy of Entolimod as a Radiation Countermeasure up to 48 Hours After Exposure of Nonhuman Primates to Lethal Radiation

BUFFALO, NY--(Marketwired - Sep 16, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the publication in the scientific journal, PLOS ONE, of studies demonstrating the ability of...
September 02, 2015 11:48 ET | Source: Cleveland BioLabs, Inc.

Department of Defense Awards Cleveland BioLabs a $9.2 Million Contract for Advanced Development of Entolimod as a Medical Radiation Countermeasure

BUFFALO, NY--(Marketwired - Sep 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Department of Defense (DoD) office of Congressionally Directed Medical Research...
September 02, 2015 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at Rodman & Renshaw 17th Annual Global Investment Conference

BUFFALO, NY--(Marketwired - Sep 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Rodman & Renshaw 17th Annual Global Investment...
August 18, 2015 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces New Patents Strengthening Entolimod Portfolio

BUFFALO, NY--(Marketwired - Aug 18, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance or issuance of several new patents for entolimod in the U.S. and other countries,...
August 12, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Reports Second Quarter 2015 Financial Results and Development Progress

BUFFALO, NY--(Marketwired - Aug 12, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter and for the six-month period...